MELANOMA STAGE III
Clinical trials for MELANOMA STAGE III explained in plain language.
Never miss a new study
Get alerted when new MELANOMA STAGE III trials appear
Sign up with your email to follow new studies for MELANOMA STAGE III, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a rheumatoid arthritis drug tame immunotherapy side effects?
Disease control OngoingThis study tests whether infliximab, a drug used for inflammatory conditions, can treat colitis (colon inflammation) caused by immune checkpoint inhibitors in people with stage III or IV skin cancer. About 42 participants will receive either infliximab or steroids, and researcher…
Matched conditions: MELANOMA STAGE III
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug cocktail aims to shrink melanoma before surgery
Disease control OngoingThis phase II trial tests two drugs, pembrolizumab and lenvatinib, given before surgery to people with stage III melanoma that can be removed. The goal is to see if the combination can shrink or eliminate the tumor before the operation. Twenty-one participants will receive the dr…
Matched conditions: MELANOMA STAGE III
Phase: PHASE2 • Sponsor: Melanoma Institute Australia • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New PET scan may reveal if immunotherapy is working in melanoma
Disease control OngoingThis phase 2 trial is testing whether giving two immunotherapy drugs, nivolumab and ipilimumab, before surgery can shrink stage III melanoma tumors and prevent the cancer from returning. The 28 participants will also receive an experimental PET scan that images immune cells to se…
Matched conditions: MELANOMA STAGE III
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New drug aims to unmask melanoma to the immune system
Disease control OngoingThis early-stage trial tests a new oral drug, SX-682, combined with the immunotherapy pembrolizumab in people with advanced melanoma. The goal is to see if SX-682 can stop cancer from hiding from the immune system, making the immunotherapy work better. About 77 participants will …
Matched conditions: MELANOMA STAGE III
Phase: PHASE1 • Sponsor: Syntrix Biosystems, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
DNA vaccines aim to supercharge immune therapy against skin cancer
Disease control OngoingThis phase 2 trial is testing two experimental DNA vaccines, SCIB1 and iSCIB1+, in combination with standard immunotherapy drugs for people with advanced melanoma that cannot be removed by surgery. The study involves 173 participants and aims to see if adding these vaccines is sa…
Matched conditions: MELANOMA STAGE III
Phase: PHASE2 • Sponsor: Scancell Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Immunotherapy after surgery may keep melanoma from coming back
Disease control OngoingThis study tests whether giving the immunotherapy drug nivolumab before and after surgery for stage III melanoma can help prevent the cancer from returning. About 67 adults with resectable melanoma will receive one dose of nivolumab before surgery, then after surgery they will ge…
Matched conditions: MELANOMA STAGE III
Phase: PHASE2 • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New combo therapy aims to shrink melanoma before surgery
Disease control OngoingThis study tests whether giving one or two immunotherapy drugs before surgery can shrink advanced melanoma (stage III or IV) that can be removed. About 48 adults with operable melanoma will receive either a single drug (dostarlimab) or a combination (dostarlimab plus cobolimab) b…
Matched conditions: MELANOMA STAGE III
Phase: PHASE2 • Sponsor: Diwakar Davar • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New keytruda copycat tested in melanoma trial
Disease control OngoingThis study tests whether FYB206, a biosimilar (or copycat) of the cancer drug Keytruda, works similarly in the body. It involves 96 people with stage IIB/IIC or III melanoma that was completely removed by surgery. Participants receive either FYB206 or Keytruda, and researchers co…
Matched conditions: MELANOMA STAGE III
Phase: PHASE1 • Sponsor: Formycon AG • Aim: Disease control
Last updated Jun 26, 2026 14:08 UTC